BioMarin Pharmaceutical Inc
BMRN58.920USD
+0.780+1.34%
交易中 （美東）報價延遲15分鐘
11.30B總市值
21.57本益比TTM
關於 BioMarin Pharmaceutical Inc 公司
BioMarin Pharmaceutical Inc. (BioMarin) 是一家生物技術公司，致力於開發和商業化解決遺傳病根源的療法。BioMarin 的商業產品包括 Vimizim (elosulfase alpha)、Naglazyme (galsulfase)、Palynziq (pegvaliase-pqpz)、Brineura (cerliponase alfa)、Aldurazyme (laronidase)、Roctavian (valoctocogene roxaparvovec)、Kuvan (sapropterin dihydrochloride) 和 Voxzogo (vosoritide)。Vimizim 是一種酶替代療法，用於治療溶酶體貯積症 MPS IVA。Roctavian 是一種腺相關病毒 (AAV5) 載體基因療法，旨在恢復重度血友病 A 患者的血漿因子 VIII 濃度。Voxzogo 是一種每日一次注射的 C 型利鈉肽 (CNP) 類似物，用於治療軟骨發育不全。 Brineura 是一種重組人三肽基肽酶 1 (TPP1)，用於治療患有 CLN2（一種巴頓病）的患者。
公司簡介
公司代碼BMRN
公司名稱BioMarin Pharmaceutical Inc
上市日期Jul 23, 1999
CEOMr. Alexander Hardy
員工數量3040
證券類型Ordinary Share
年結日Jul 23
公司地址770 Lindaro Street
城市SAN RAFAEL
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94901
電話14155066700
網址https://www.biomarin.com/
公司代碼BMRN
上市日期Jul 23, 1999
CEOMr. Alexander Hardy
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Ms. Erin Burkhart
Ms. Erin Burkhart
Group Vice President, Chief Accounting Officer
Group Vice President, Chief Accounting Officer
14.18K
-16.41%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
地區USD
名稱
營收
佔比
United States
241.69M
32.90%
Europe
229.58M
31.25%
Rest of the world
126.11M
17.17%
Latin America
88.28M
12.02%
ALDURAZYME net product revenues marked by Sanofi
48.98M
6.67%
業務
地區
業務USD
名稱
營收
佔比
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
股東統計
更新時間: 5月18日 週日
更新時間: 5月18日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.87%
BlackRock Institutional Trust Company, N.A.
9.45%
PRIMECAP Management Company
9.27%
Dodge & Cox
7.80%
Viking Global Investors LP
5.63%
Other
57.99%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.87%
BlackRock Institutional Trust Company, N.A.
9.45%
PRIMECAP Management Company
9.27%
Dodge & Cox
7.80%
Viking Global Investors LP
5.63%
Other
57.99%
股東類型
持股股東
佔比
Investment Advisor
48.68%
Investment Advisor/Hedge Fund
35.44%
Hedge Fund
8.14%
Pension Fund
2.77%
Sovereign Wealth Fund
2.02%
Research Firm
1.30%
Bank and Trust
1.11%
Individual Investor
0.75%
Venture Capital
0.26%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
1323
192.81M
100.54%
-18.92M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
2023Q1
1274
186.38M
99.36%
-9.64M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
18.92M
9.87%
-369.57K
-1.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.12M
9.45%
-16.94K
-0.09%
Mar 31, 2025
PRIMECAP Management Company
17.77M
9.27%
-415.89K
-2.29%
Mar 31, 2025
Dodge & Cox
14.96M
7.8%
+209.00K
+1.42%
Mar 31, 2025
Viking Global Investors LP
10.80M
5.63%
+289.51K
+2.75%
Mar 31, 2025
Capital Research Global Investors
9.15M
4.77%
-3.84M
-29.57%
Mar 31, 2025
State Street Global Advisors (US)
8.46M
4.41%
-649.18K
-7.12%
Mar 31, 2025
Columbia Threadneedle Investments (US)
3.62M
1.89%
-171.27K
-4.52%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.57M
1.86%
-49.67K
-1.37%
Dec 31, 2024
Elliott Management Corporation
3.50M
1.83%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Biotechnology & Genome ETF
4.61%
Global X Genomics & Biotechnology ETF
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.04%
Goldman Sachs Future Health Care Equity ETF
2.69%
WealthTrust DBS Long Term Growth ETF
2.36%
SPDR S&P Biotech ETF
2.34%
Motley Fool Mid-Cap Growth ETF
1.87%
Virtus LifeSci Biotech Products ETF
1.85%
Alger Russell Innovation ETF
1.67%
VanEck Biotech ETF
1.53%
查看更多
Invesco Biotechnology & Genome ETF
佔比4.61%
Global X Genomics & Biotechnology ETF
佔比3.49%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.04%
Goldman Sachs Future Health Care Equity ETF
佔比2.69%
WealthTrust DBS Long Term Growth ETF
佔比2.36%
SPDR S&P Biotech ETF
佔比2.34%
Motley Fool Mid-Cap Growth ETF
佔比1.87%
Virtus LifeSci Biotech Products ETF
佔比1.85%
Alger Russell Innovation ETF
佔比1.67%
VanEck Biotech ETF
佔比1.53%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
